The Epidemiology and Clinical Research Unit (ECRU) of the National Neuroscience Institute was formed to provide a hub for epidemiological and clinical research in the clinical neurosciences. The ECRU will also serve to facilitate the process of establishing and conducting clinical trials at the NNI by providing suitable manpower, office space, co-ordinating facilities and support.

A community-based prevalence survey of neurological diseases in Singapore.

Aim: This study is to determine the prevalence of 4 major neurological diseases in the older Singapore population - dementia, epilepsy, parkinsonism and stroke.

Methodology: The study population was drawn from a stratified random sample of 25,000 study subjects aged 50 years and above living in the central part of Singapore. Respondants were screened using validated screening tools during face-to-face interviews. Those screened positive were invited to a Phase II screen for definitive diagnosis.

IMAGES: Intravenous Magnesium Efficacy in stroke.
Sponsor: MRC/UK Phase: III Subject No.: 383

ESPRIT: European & Australasian Stroke Prevention in Reversible Ischaemia Trial.
Sponsor: European Union Phase: IV Subject No.: 292

CRASH: Corticosteriod Randomization after Significant Head Injury.
Sponsor: MRC/UK Phase: IV Subject No.: 14

VITATOPS: VITamins TO Prevent Stroke Trial.
Sponsor: NHMRC Phase: III Subject No.: 257

DIAS: Desmoteplase (INN) in Acute Ischaemic
Stroke. Sponsor: PAION GmbH Phase: II Subject No.: 3

MATCH: Management of Atherothrombosis with Clopidogrel in High-risk patients with recent TIA or Stroke.
Sponsor: Sanofi-Synthelabo Phase: III Subject No.: 136

FISS-tris: Fraxiparine In Stroke Study.
Sponsor: HKHA Phase: III Subject No.: 3

ENOS: Efficacy of Nitric Oxide in Stroke.
Sponsor: PPP Phase: III Subject No.: 18

NOVO SEVEN: Activated Recombinant Factor VII in Acute Intracerebral Haemorrhage.
Sponsor: Novo Nordisk Phase: II Subject No.: 7

ONTARGET: Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial.
Sponsor: Boehringer-Ingelheim Phase: IV Subject No.: 16

Sumanirole vs placebo or ropinirole, as an adjuvant to levodopa, in patients with advanced Parkinson's Disease.
Sponsor: Pharmacia Phase: III Subject No.: 12

Topiramate as an add on therapy in medically intractable epilepsy.
Sponsor: Janssen Phase: IV Subject No.: 32

Treating relapsing-remitting multiple sclerosis with Glyco-Feron, a recombinant human beta-Interferon.
Sponsor: IMCB Phase: II Subject No.: 8

Efficacy & Safety of Nimodipine in the treatment of Traumatic Subarachnoid Haemorrhage: A multi-centre, double blind, placebo-controlled study
Sponsor: Bayer Phase: III Subject No.: 36

PASS-II: To evaluate the Efficacy & Safety of Piracetam in Acute Ischaemic Middle Cerebral Artery Stroke.
Sponsor: UCB Phase: III Subject No.: 67

GAIN: A study of GV150526 in the treatment of Acute Stroke.
Sponsor: Glaxo-Wellcome Phase: III Subject No.: 80

POST: A trial of 2 Intravenous doses of BMS-204352 in Acute Stroke.
Sponsor: Bristol-Myers Squibb Company Phase: II Subject No.: 33

Eletriptan in migraine.
Sponsor: Pfizer Phase: IV Subject No.: 16

The National Neuroscience Institute has a talented group of clinicians, scientists and trials coordinators capable of conducting clinical trials to Good Clinical Practice standards at both campuses. As we have access to large patient populations, swift enrolment into trials is the norm.

Our current focus is on developing a regional trials coordinating centre for larger scale trials as well as enhancing our capability for conducting increasingly sophisticated Phase II studies utilising biomarkers such as neuroimaging, neurochemistry and molecular biology. We also aim to develop further synergy with our basic neuroscience research.


CONTACT PERSON

For General enquiries:

Research Administration
Tel : (65) 6357 7610
Fax: (65) 6256 9178